TARGET PharmaSolutions Takes Aim At Immune-Mediated Inflammatory Skin Conditions

Creative Commons License Source:  Gerd Altmann , no changes made.
Advertisement

TARGET PharmaSolutions, Inc., a company focused on real-world evidence, has announced that it launched its latest large-scale observational study, TARGET-DERM (NCT03661866).  The study will deliver real-world evidence for several immune-mediated inflammatory skin conditions (IMISCs), initially focusing on patients with atopic dermatitis (AD/eczema).

TARGET PharmaSolutions, founded in 2015, headquartered in Chapel Hill, North Carolina, USA, is a privately held real-world data solutions company that provides pharmaceutical and biotechnology partners a more efficient way to generate data in the real-world setting.

TARGET-DERM’s first participant enrolled on January 25, 2019.  The trial will enroll up to 15,000 participants, including adult and pediatric patients, at up to 100 sites in the United States, Canada and Europe.  TARGET-DERM will eventually include the skin conditions hidradenitis suppurativa (painful bumps under the skin), alopecia areata (autoimmune-related hair loss), and vitiligo (loss of skin pigment). TARGET-DERM will collect three years of retrospective data and five years of prospective data on its participants.  This data will also be connected to an extensive biorepository which TARGET-DERM stakeholders can access for genomic studies and translational research.

TARGET-DERM will create a research registry of patients with immune-mediated inflammatory skin conditions within academic and community real-world practices to assess the safety and effectiveness of current and future therapies. TARGET-DERM is led by an academic steering committee chaired by Emma Guttman-Yassky, MD, The Sol and Clara Kest Professor of Dermatology and Immunology, and Vice Chair, department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, and Diamant Thaçi, MD, Professor and Head, Comprehensive Center for Inflammation Medicine, University of Lubeck, Germany.

“We are excited to initiate enrollment and to advance the important work of further understanding inflammatory skin diseases and particularly AD, through this TARGET-DERM registry.” … “There are many critical, unanswered questions regarding the mechanisms underlying eczema and these other complex immune-mediated skin conditions.  TARGET-DERM is a unique opportunity to better understand the natural history of AD and other diseases and to evaluate different treatment regimens, outcomes and adverse events across a large, diverse patient population.  It is our hope that this research can better inform how these conditions are approached and ultimately improve the lives of the millions of people who suffer from them.” – Dr. Emma Guttman-Yassky

Sources:

  1. https://www.prnewswire.com/news-releases/target-pharmasolutions-launches-target-derm-real-world-observational-study-to-advance-the-understanding-of-atopic-dermatitis-eczema-and-other-immune-mediated-inflammatory-skin-conditions-300794533.html
  2. https://www.crunchbase.com/organization/target-pharmasolutions#section-overview
Advertisement

David is a consultant/medical writer for a number of ongoing healthcare initiatives including for Athla LLC/ HealthLabs, a discovery automation company for Big Data leveraging Big Compute. He has a number of years experience in academic R&D and healthcare related projects including the fields of oncology and immunotherapy.